WHO issues global guideline on the use of GLP-1 medicines in treating obesity

ABC News

World Health Organization issues first-ever guidelines for use of GLP-1 weight loss medications

JAMA Network

World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults

Sky News

Weight loss jabs conditionally backed to tackle obesity by World Health Organization

The Hill

WHO releases its first guidelines on GLP-1s

The Telegraph

WHO recommends weight loss jabs to treat obesity around the world

News.com.au

WHO declares obesity a chronic disease, makes historic Ozempic decision

The Pharmaceutical Journal

Weight loss drugs: the wrong answer to the obesity problem

Weight Loss Drugs Not The Answer To Britain Obesity Problem

WHO recommends GLP-1 drugs for obesity

Metaculus

Glp 1 Based Drug Approval By 2029

WHO updates list of essential medicines to include key cancer, diabetes treatments

The World Health Organization released its first guideline on the use of Glucagon-Like Peptide-1 therapies for treating obesity, affecting more than 1 billion people globally, with the number projected to double by 2030 without decisive action.

The World Health Organization released its first guideline on the use of Glucagon-Like Peptide-1 therapies for treating obesity, affecting more than 1 billion people globally, with the number projected to double by 2030 without decisive action.

The WHO issued conditional recommendations for GLP-1 therapies, including semaglutide, liraglutide and tirzepatide, for long-term treatment of obesity in adults excluding pregnant women, emphasizing limited data on long-term efficacy and safety.

The WHO issued conditional recommendations for GLP-1 therapies, including semaglutide, liraglutide and tirzepatide, for long-term treatment of obesity in adults excluding pregnant women, emphasizing limited data on long-term efficacy and safety.

Obesity was associated with 3.7 million deaths worldwide in 2024, and the global economic cost is predicted to reach $3 trillion annually by 2030, driving efforts to reduce health costs associated with managing the condition and its complications.

Obesity was associated with 3.7 million deaths worldwide in 2024, and the global economic cost is predicted to reach $3 trillion annually by 2030, driving efforts to reduce health costs associated with managing the condition and its complications.

The WHO emphasized that GLP-1 therapies should be combined with intensive behavioral interventions involving healthy diet and physical activity, as medication alone will not solve the obesity challenge, which requires comprehensive and lifelong care.

The WHO emphasized that GLP-1 therapies should be combined with intensive behavioral interventions involving healthy diet and physical activity, as medication alone will not solve the obesity challenge, which requires comprehensive and lifelong care.

Even with rapid expansion in production, GLP-1 therapies are projected to reach fewer than 10% of those who could benefit by 2030, prompting the WHO to call for strategies to expand access such as pooled procurement and tiered pricing to address equity concerns.

Even with rapid expansion in production, GLP-1 therapies are projected to reach fewer than 10% of those who could benefit by 2030, prompting the WHO to call for strategies to expand access such as pooled procurement and tiered pricing to address equity concerns.

The WHO added GLP-1 therapies to its Essential Medicines List for managing type 2 diabetes in high-risk groups in September 2025, and the new guideline represents a shift toward treating obesity as a chronic disease deserving lifelong care.

The WHO added GLP-1 therapies to its Essential Medicines List for managing type 2 diabetes in high-risk groups in September 2025, and the new guideline represents a shift toward treating obesity as a chronic disease deserving lifelong care.

WHO Issues First Guidelines for GLP-1 Obesity Treatments

WHO Issues First Guidelines for GLP-1 Obesity Treatments

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters

WHO Issues First Guidelines for GLP-1 Obesity Treatments

WHO Issues First Guidelines for GLP-1 Obesity Treatments

Sign Up for Our Free NewslettersSign Up for Our Free Newsletters

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters